Cynosure to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference

WESTFORD, Mass., Nov. 29, 2011 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that it will present at Canaccord Genuity's  6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference at 1:20 p.m. (ET) on Tuesday, December 6 in San Francisco.

The presentation by Cynosure President and CEO Michael Davin and Executive Vice President, Treasurer and CFO Timothy Baker will be available via live and archived audio webcast accessible through a link on the Investor Relations section of the Company's website, www.cynosure.com.  

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce the appearance of cellulite and treat Onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

617.542.5300

[e-mail]

SOURCE Cynosure, Inc.

Copyright 2011 PR Newswire